All In Biotech

Drug Trial Radar · NCT03913195

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

A Phase 3 Study of the Safety of Trogarzo® Administered as an Undiluted "IV Push" Over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo® Experienced Patients and Healthy HIV-uninfected Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

43

Actual

Start

May 30, 2019

Primary completion

Oct 17, 2022

Study completion Oct 31, 2022

Sponsor

Lead sponsor
TaiMed Biologics Inc.Industry
Sponsor type
Industry
Collaborators
Westat
First posted
Apr 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo once every two weeks administered via "IV Push" or intramuscular injection. An initial "Sentinel Group" of 5 participants will begin receiving 800mg Trogarzo on a gradual schedule of increasing concentration and decreasing administration time until undiluted IV Push over 30 seconds is achieved, while safety and pharmacokinetics are evaluated. If no safety signals are seen, the Core Group of 15 participants will be enrolled. The Core Group will receive 800mg Trogarzo via undiluted IV Push over 30 seconds while safety and pharmacokinetics are monitored. After completion of the IV Push portion of the study, a second group of 20 participants will be enrolled to evaluate the safety and pharmacokinetics of administration of 800mg via intramuscular injection.

Conditions

  • HIV-1-infection

Interventions

  • ibalizumab-uiykDrug

    Ibalizumab-uiyk is an Immunoglobulin G4 (IgG4) monoclonal antibody targeting domain 2 of the extracellular portion of the Cluster of Differentiation 4 (CD4) protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Trogarzo Given as IV Push Over 30 SecondsTime frame: 12 weeks
  2. Pharmacokinetics Bridge for IV Push and IV Infusion (Ctrough)Time frame: Day 1 infusion versus Day 85 IV Push
  3. Pharmacokinetics Bridge for IV Push and IV Infusion (AUC)Time frame: Day 1 infusion versus Day 85 IV Push
  4. Safety of Trogarzo Given as an Intramuscular Injection in the Intramuscular Injection GroupTime frame: 10 weeks
  5. Pharmacokinetics Bridge Demonstrated for Intramuscular Injection of Trogarzo and IV InfusionTime frame: Day 1 infusion versus Day 71 intramuscular injection

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Anthony Mills MD Inc.

    Los Angeles, California

  • Gary Richmond MD, PA

    Fort Lauderdale, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • North Texas Infectious Disease Consultants

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.